118P Role of PD-L1 and Pathological Complete Response (pcr) with Neoadjuvant (NEO) or Perioperative (PERIOP) Immune-Checkpoint Inhibitors (ICI) and Platinum-Based Chemotherapy (PCT) in Resectable Non-Small Cell Lung Cancer (NSCLC): A Systematic Review and Metanalysis

A previous metanalysis showed no significant subgroup interaction between PD-L1 and pCR, while both PD-L1 status and pCR significantly correlated with better event free survival (EFS). Overall, no difference in EFS between NEO and PERIOP strategies was reported by indirect comparison (Nuccio et al). Additional RCTs and updated results of previous studies could help to define the role of PD-L1 and pCR and the best treatment strategy according to these variables.